During the COVID-19 pandemic, fungal infections became a serious complication in hospitalized patients, especially those receiving steroids and other immune-suppressing treatments. Common fungal pathogens like Candida and Aspergillus caused dangerous coinfections, with infection rates varying significantly by region. Current antifungal medications have significant limitations including toxicity and resistance, highlighting the urgent need for new and safer antifungal treatments.